Metalloproteomics for molecular target identification of protein-binding anticancer metallodrugs,Metallomics

当前位置： X-MOL 学术 › Metallomics › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Metalloproteomics for molecular target identification of protein-binding anticancer metallodrugs
Metallomics ( IF 2.9 ) Pub Date : 2020-10-08 , DOI: 10.1039/d0mt00196a
Tasha R Steel ₁ , Christian G Hartinger

Affiliation

Proteomics has played an important role in elucidating the fundamental processes occuring in living cells. Translating these methods to metallodrug research (‘metalloproteomics’) has provided a means for molecular target identification of metal-based anticancer agents which should signifcantly advance the research field. In combination with biological assays, these techniques have enabled the mechanisms of action of metallodrugs to be linked to their interactions with molecular targets and aid understanding of their biological properties. Such investigations have profoundly increased our knowledge of the complex and dynamic nature of metallodrug–biomolecule interactions and have provided, at least for some compound types, a more detailed picture on their specific protein-binding patterns. This perspective highlights the progression of metallodrug proteomics research for the identification of non-DNA targets from standard analytical techniques to powerful metallodrug pull-down methods.

中文翻译：

用于蛋白质结合抗癌金属药物分子靶标鉴定的金属蛋白质组学

蛋白质组学在阐明活细胞中发生的基本过程方面发挥了重要作用。将这些方法转化为金属药物研究（“金属蛋白质组学”）为基于金属的抗癌药物的分子靶标鉴定提供了一种手段，这将显着推进研究领域。结合生物测定，这些技术使金属药物的作用机制与它们与分子靶标的相互作用相关联，并有助于了解它们的生物学特性。此类研究极大地增加了我们对金属药物-生物分子相互作用的复杂性和动态性的认识，并且至少对某些化合物类型提供了有关其特定蛋白质结合模式的更详细的图片。

更新日期：2020-11-03

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11